Filters
A retrospective cohort study evaluating participants from Catalonia, Spain reinforces the potential of immunoprophylaxis with the novel monoclonal antibody nirsevimab in combating respiratory syncytial virus (RSV)-related outcomes in infants in the hospital and primary care settings.
Consumption of sugar-sweetened beverages in early childhood tends to lead to a less healthy dietary pattern and greater adiposity during adulthood, reveals a study.
A novel miniaturized implantable continuous flow left ventricular assist device, the Jarvik 2015, has the potential to allow small children with heart failure to go home while awaiting heart transplant and shorten hospital stays.
Secondary transmission of pertussis, also known as whooping cough, is highly prevalent in the household setting, according to a study, adding that delays in diagnosis can heighten the odds of spreading pertussis in the home.
Use of antibiotics appears to increase the risk of Kawasaki disease (KD) in children, reveals a study. KD development is potentially driven by gut microbiota changes due to antibiotic use.
Using data from the parent-offspring GUSTO* cohort study, researchers found an association between parental practices and higher moderate-to-vigorous physical activity (MVPA) and lower inactivity among school-aged Singaporean children.
Delayed presentation to the emergency department (ED) >24 hours after fever onset was associated with an increased risk of serious bacterial infection (SBI) in febrile infants, according to a Singapore study.
Exposure to valproate during spermatogenesis does not appear to put infants at risk of congenital malformations or neurodevelopmental disorders, including autism spectrum disorder, according to a study.
For teenagers with idiopathic scoliosis who wear a corrective brace, gradual removal of the device offers no significant advantage over immediate removal in terms of bracing outcomes and quality of life, according to the results of an open-label randomized clinical trial in Hong Kong.
New drug applications approved by US FDA as of 16-31 May 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
